Pfizer Inc (NYSE: PFE) is reportedly exploring options for some early-stage candidates for rare diseases, including developing new viral-based gene therapies.
Financial newspaper Barron’s first reported on Thursday.
The U.S. pharma giant said these options included collaborations with other drug developers for these medicines or establishing a new company, with an aim to focus on “high-impact” medicines and vaccines.
Also see: Pfizer Expects $10-$15B From mRNA Vaccine Sales By 2030, Sees $17B Revenues …
The Rise of FinTech: Transforming Personal Finance and Investment
February 15, 2024
